OBJECTIVE: To determine the feasibility and safety of image-guided brachytherapy employing a modified open high-field MR system. METHODS: This is a follow-up study of a development project enabling technologies for interventional use of 1.0T open MRI. Modifications included coils and in-bore visualization, fluoroscopic sequences and user interfaces. We recruited 104 patients with 224 liver malignancies to receive MR-guided brachytherapy. Interventions were performed >20 min after Gd-EOB-DTPA. We recorded interventional parameters including the intervention time (from acquisition of the first scout until the final sequence for brachytherapy treatment planning). Two reviewers assessed MR-fluoroscopic images in comparison to plain CT as used in CT intervention, applying a rating scale of 1-10. Statistical analysis included Friedman and Kendall's W tests. RESULTS: We employed freehand puncture with interactive dynamic imaging for navigation. Technical success rate was 218 complete ablations in 224 tumours (97%). The median intervention time was 61 min. We recorded no adverse events related to the use of MRI. No major complications occurred. The rate of minor complications was 4%. Local control at 3 months was 96%. Superiority of MR-fluoroscopic, Gd-EOB-DTPA-enhanced images over plain CT was highly significant (P < 0.001). CONCLUSION: MR-guided brachytherapy employing open high-field MRI is feasible and safe.
OBJECTIVE: To determine the feasibility and safety of image-guided brachytherapy employing a modified open high-field MR system. METHODS: This is a follow-up study of a development project enabling technologies for interventional use of 1.0T open MRI. Modifications included coils and in-bore visualization, fluoroscopic sequences and user interfaces. We recruited 104 patients with 224 liver malignancies to receive MR-guided brachytherapy. Interventions were performed >20 min after Gd-EOB-DTPA. We recorded interventional parameters including the intervention time (from acquisition of the first scout until the final sequence for brachytherapy treatment planning). Two reviewers assessed MR-fluoroscopic images in comparison to plain CT as used in CT intervention, applying a rating scale of 1-10. Statistical analysis included Friedman and Kendall's W tests. RESULTS: We employed freehand puncture with interactive dynamic imaging for navigation. Technical success rate was 218 complete ablations in 224 tumours (97%). The median intervention time was 61 min. We recorded no adverse events related to the use of MRI. No major complications occurred. The rate of minor complications was 4%. Local control at 3 months was 96%. Superiority of MR-fluoroscopic, Gd-EOB-DTPA-enhanced images over plain CT was highly significant (P < 0.001). CONCLUSION: MR-guided brachytherapy employing open high-field MRI is feasible and safe.
Authors: H Zimmermann; S Müller; B Gutmann; H Bardenheuer; A Melzer; R Umathum; W Nitz; W Semmler; M Bock Journal: Magn Reson Med Date: 2006-09 Impact factor: 4.668
Authors: T Douglas Mast; Daniel P Pucke; Swetha E Subramanian; William J Bowlus; Steven M Rudich; Joseph F Buell Journal: J Ultrasound Med Date: 2008-12 Impact factor: 2.153
Authors: Sebastian Kos; Rolf Huegli; Eugen Hofmann; Harald H Quick; Hilmar Kuehl; Stephanie Aker; Gernot M Kaiser; Paul J Borm; Augustinus L Jacob; Deniz Bilecen Journal: Invest Radiol Date: 2009-04 Impact factor: 6.016
Authors: F Collettini; A C Schippers; D Schnapauff; T Denecke; B Hamm; H Riess; P Wust; B Gebauer Journal: Br J Radiol Date: 2013-05-09 Impact factor: 3.039
Authors: Florian Streitparth; T Hartwig; B Schnackenburg; P Strube; M Putzier; S Chopra; M De Bucourt; B Hamm; U Teichgräber Journal: Eur Radiol Date: 2010-11-30 Impact factor: 5.315
Authors: Marko Rak; Tim König; Klaus D Tönnies; Mathias Walke; Jens Ricke; Christian Wybranski Journal: Int J Comput Assist Radiol Surg Date: 2017-07-06 Impact factor: 2.924
Authors: Frank Fischbach; Peter Hass; Daniel Schindele; Philipp Genseke; Lisa Geisendorf; Christian Stehning; Martin Schostak; Thomas Brunner; Maciej Pech; Katharina Fischbach Journal: Eur Radiol Date: 2019-12-11 Impact factor: 5.315